Physician profile
John B Patterson
NPI 1073573226
$75,116.83
in general payments reported to CMS, 2019-2025
38 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $6,122 · 2021: $23K · 2022: $9,343 · 2023: $2,119 · 2024: $2,638 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,860 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,550 · Education: $52.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,860.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,550.00 |
| Education | $52.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $38,103.57 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28,105.81 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $3,876.61 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $819.43 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $595.72 | 2019-2025 | Brilinta, Farxiga |
| Amgen INC. | $377.68 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $363.80 | 2022-2025 | Verquvo |
| Irhythm Technologies, INC. | $349.98 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.49 | 2019-2025 | Jardiance |
| Abbott Laboratories | $203.90 | 2019-2022 | |
| Boston Scientific Corporation | $184.62 | 2020-2025 | Watchman Flx, Ekosonic, Bodyguardian |
| Penumbra, INC. | $153.21 | 2020-2022 | |
| Pfizer INC. | $152.30 | 2019-2025 | |
| Medtronic Vascular, INC. | $136.47 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $132.28 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $125.77 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $123.64 | 2023-2024 | Wegovy, Ozempic |
| Astellas Pharma US INC | $117.45 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $105.02 | 2019-2021 | |
| Ekos Corporation | $98.33 | 2019 | |
| Philips North America LLC | $93.38 | 2022-2024 | (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
| Lundbeck LLC | $89.14 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.85 | 2023-2025 | |
| Cardiovascular Systems INC. | $80.58 | 2019 | |
| Inari Medical, INC. | $64.31 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kiniksa Pharmaceuticals, LTD. | $50.75 | 2022 | |
| Medtronic, INC. | $43.64 | 2022 | |
| Shockwave Medical, INC | $32.03 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Vifor Pharma, INC. | $29.01 | 2019 | |
| Celonova Biosciences, INC. | $25.23 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $23.76 | 2024 | Arcalyst |
| Abiomed | $23.68 | 2025 | |
| Amarin Pharma, INC. | $23.60 | 2019 | |
| Cvrx, INC. | $22.54 | 2024 | Barostim Neo System |
| Arbor Pharmaceuticals, INC. | $13.56 | 2019 | |
| Lantheus Medical Imaging, INC. | $13.28 | 2023 | Definity |
| Advanced Oxygen Therapy INC. | $13.04 | 2025 | Topical Oxygen Chamber For Extremities |
| Reflow Medical INC | $3.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.